Andere talen Aligos Therapeutics, Inc.

Aandelen

ALGS

US01626L1052

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,782 ^USD	-4,40%		+4,27%	+17,77%

03/04	Aligos Therapeutics, Inc. Kondigt aan dat de eerste proefpersonen gedoseerd zijn in de Fase 2a HERALD-studie van ALG-055009 bij MASH proefpersonen	CI
27/03	Aligos Therapeutics presenteert positieve klinische gegevens van ALG-055009 en ALG-000184 fase 1-studies op APASL 2024	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study	25/04
Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study	25/04
Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD	25/04
Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD	25/04
Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024	09/04
Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects	03/04
Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects	03/04
Aligos Therapeutics, Inc. Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects	03/04
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies	27/03
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies	27/03
Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects	18/03
Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects	18/03
Aligos Therapeutics, Inc. Announces the Initiation of the Phase 2a HERald Study of ALG-055009 in MASH Subjects	18/03
Aligos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	12/03
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results	12/03
Aligos Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	12/03
Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024	05/03
Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024	26/02
Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024	20/02
Aligos Therapeutics Strengthens Finance Leadership Team with Two New Appointments	13/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Aligos Therapeutics, Inc.

Aandelen

ALGS

US01626L1052

Andere talen

Filters